BioSpace News Archive

Provectus Biopharmaceuticals, Inc. were presented at the annual meeting of the Association for Research in Vision and Ophthalmology (“ARVO”), held May 5-9, 2024 in Seattle, Washington.

Palisade Bio, Inc. today reported its financial results for the first quarter 2024 and provided a business update.

Ocugen, Inc. today reported first quarter 2024 financial results along with a general business update.

Children’s Hospital of Philadelphia announced that it has received a significant philanthropic gift from Mitchell L. Morgan, Dr. Hilarie L. Morgan and their family to name its state-of-the-art research facility currently under construction on the South Street bridge next to CHOP’s Roberts Center for Pediatric Research.

Halia Therapeutics today announced the unveiling of a new clinical program evaluating its candidate HT-4253 for the treatment of Alzheimer’s disease.

Akebia Therapeutics®, Inc. announced that John Butler, Chief Executive Officer, will participate in a fireside chat at the 2nd Annual HCW Bioconnect Investor Conference on Monday, May 20th, 2024 at 3:00 p.m. ET.

CASI Pharmaceuticals, Inc. today reported financial results for the three months ended March 31, 2024.

Precision for Medicine, a global leader in biomarker-driven clinical research and development supporting life sciences companies, announced the completion of a major expansion to its laboratory campus in Frederick, Maryland.

Verismo Therapeutics today announced that it has received a notification from the US Food and Drug Administration (FDA) that the Phase 1 clinical trial of SynKIR™-310 for the investigation of NHL may proceed.

Elegen, the leader in next-generation DNA synthesis and production, announced a Series B financing of $35 million led by Triatomic Capital.